Abcuro
Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases
$66MSeries D
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
AI-driven platform that simulates clinical trials to predict outcomes before patient enrollment
Pitching Sanofi Ventures? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room